Envista raises 2026 profit forecast, Q3 earnings top estimates

Envista (NVST) topped third-quarter profit estimates and raised its full-year profit forecast, the company said Nov. 4 in its results release.

Adjusted diluted earnings per share were 40 cents for the quarter ended Oct. 2, above the 36-cent consensus estimate and up from 32 cents a year earlier.

Sales were $691.5 million, below the $702.51 million consensus estimate and up from $669.9 million a year earlier.

Under generally accepted accounting principles, net income was $508.3 million, or $3.11 per diluted share, compared with a net loss of $30.3 million a year earlier. That figure includes a foreign currency translation gain of $428 million in operating profit, or $2.62 per diluted share before tax effects, the company said.

The company said the gain came from releasing cumulative translation adjustments tied to the dissolution of certain legal entities. It had no cash impact and no effect on adjusted EBITDA, adjusted operating income or adjusted diluted EPS.

Here's how the company did:

• Adjusted diluted EPS: 40 cents vs. 32 cents a year earlier, against 36 cents expected
• Sales: $691.5 million vs. $669.9 million a year earlier, against $702.51 million expected
• GAAP diluted EPS: $3.11 vs. a loss of 18 cents a year earlier
• Adjusted EBITDA: $105.8 million vs. $97.1 million a year earlier

2026 guidance

Envista raised its 2026 forecast. Core sales growth is now expected at 3.75% to 4.25%, up from the 3.5% to 4.5% range it gave previously.

Adjusted diluted EPS is now expected at $1.54 to $1.58, from $1.50 to $1.55. The company expects free cash flow conversion of about 100%, unchanged from its prior forecast.

"Our strong momentum and year-to-date progress give us confidence to raise our full-year earnings guidance once again," said Paul Keel, CEO.

Segment results

Specialty Products & Technologies sales were $443.7 million, with core sales growth of 2.0% over the third quarter of 2025.

Equipment & Consumables sales were $247.8 million, with core sales growth of 4.1%.

Core sales growth for the company as a whole was 2.7%. Adjusted gross margin rose 20 basis points year over year, according to the release.

Cash flow and buybacks

Operating cash flow was $78 million for the quarter, against $79 million a year earlier. Free cash flow was $63 million, compared with $68 million.

The company repurchased 386 thousand shares for about $10 million during the quarter. It had about $273 million of remaining repurchase capacity under its stock repurchase program at the end of the quarter.

Envista sells dental products through more than 30 brands, including DEXIS, Kerr, Nobel Biocare and Ormco.